#1C Columbia Care INVESTOR PRESENTATION NEO:CCHW | CSE:CCHW | OTCQX:CCHWF | FSE:3LP July 2023#2DISCLAIMER AND FORWARD-LOOKING STATEMENTS 2 Disclaimer Columbia Care Inc. (the "Company" or "Columbia Care") derives a substantial portion of its revenues from the cannabis industry in certain U.S. states, which industry is illegal under U.S. federal Law. Columbia Care is directly involved in both the adult-use and medical cannabis industry in the states of Arizona, California, Colorado, Illinois, Massachusetts, Missouri and New Jersey, and in the medical cannabis industry in the states of Delaware, Florida, Maryland, New York, Ohio, Pennsylvania, the District of Columbia, Utah, Virginia, and West Virginia, which states have regulated such industries. The cultivation, processing, sale and use of cannabis are illegal under federal law pursuant to the U.S. Controlled Substance Act of 1970 (the "CSA"). Under the CSA, the policies and regulations of the United States federal government and its agencies are that cannabis has no medical benefit and a range of activities, including cultivation and the personal use of cannabis, are prohibited. The Supremacy Clause of the United States Constitution establishes that the United States Constitution and federal laws made pursuant to it are paramount and in case of conflict between federal and state law, the federal law shall apply. Until 2018, the federal government provided guidance to federal law enforcement agencies and banking institutions through a series of United States Department of Justice ("DOJ") memoranda. The most recent such memorandum was drafted by former Deputy Attorney General James Cole in 2013 (the "Cole Memo"). On January 4, 2018, former U.S. Attorney General Jeff Sessions issued a memorandum to U.S. district attorneys that rescinded previous guidance from the U.S. Department of Justice specific to cannabis enforcement in the United States, including the Cole Memo (as defined herein). The former Attorneys General who succeeded former Attorney General Sessions following his resignation did not provide a clear policy directive for the United States as it pertains to state-legal marijuana-related activities. President Joseph R. Biden was sworn in as the 46th President of the U.S. on January 20, 2021. President Biden nominated Merrick Garland to serve as Attorney General in his administration, and he was confirmed on March 10, 2021. It is not yet known whether the Department of Justice under President Biden and Attorney General Garland will re-adopt the Cole Memorandum or announce a substantive marijuana enforcement policy. Attorney General Garland stated at a confirmation hearing before the United States Senate that "It does not seem to me a useful use of limited resources that we have, to be pursuing prosecutions in states that have legalized and that are regulating the use of marijuana, either medically or otherwise. I don't think that's a useful use." Attorney General Garland reiterated this view at a Senate Appropriations subcommittee hearing on April 26, 2022. Nonetheless, there is no guarantee that state laws legalizing and regulating the sale and use of marijuana will not be repealed or overturned, or that local governmental authorities will not limit the applicability of state laws within their respective jurisdictions. Unless and until the United States Congress amends the CSA with respect to marijuana (and as to the timing or scope of any such potential amendments there can be no assurance), there is a risk that federal authorities may enforce current U.S. federal law. Currently, in the absence of uniform federal guidance, as had been established by the Cole Memo, enforcement priorities are determined by respective United States Attorneys. Columbia Care makes no medical or treatment claims about our products, implied or otherwise, and each patient or customer should consult their treating physician, explore all options, and discuss their personal health to determine whether he or she may be a potential candidate for medical marijuana or other cannabis-derived products. Our products have not been evaluated by the Food and Drug Administration ("FDA"). In addition, our products have not been approved by the FDA to diagnose, treat, cure, or prevent any disease. In addition, we have not conducted clinical trials for the use of our products. Any references to quality, consistency, efficacy and safety of our products are not intended to imply that such claims have been verified in clinical trials. Non-GAAP Financial Measures In this presentation, Columbia Care may refer to certain non-GAAP financial measures, including, without limitation, EBITDA, Adjusted EBITDA and Adjusted Gross Margin. These measures do not have any standardized meaning in accordance with U.S. GAAP and may not be comparable to similar measures presented by other companies. Columbia Care considers certain non-GAAP measures to be meaningful indicators of the performance of its business. A reconciliation of such non-GAAP financial measures to their nearest comparable GAAP measure is included in this presentation and a further discussion of some of these items is contained in the Company's Form 10-Q for the three months ended March 31, 2023. Cautionary Note Regarding Securities Laws This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of Columbia Care, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Risk Factors For a detailed description of risk factors associated with Columbia Care, refer to the "Risk Factors" section in Columbia Care's Form 10-K for the year ended December 31, 2022, which are available on EDGAR at www.sec.gov and SEDAR at www.sedar.com. Columbia Care#3DISCLAIMER AND FORWARD-LOOKING STATEMENTS 3 Caution Concerning Forward-Looking Statements This presentation contains certain statements that constitute forward-looking information within the meaning of applicable securities laws ("forward-looking statements"). Statements concerning Columbia Care's objectives, goals, strategies, priorities, intentions, plans, beliefs, expectations and estimates, and the business, operations, financial performance and condition of Columbia Care are forward-looking statements. The words "believe", "expect", "anticipate", "estimate", "intend", "may", "will", "would", "could", "should", "continue", "plan", "goal", "objective", and similar expressions and the negative of such expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Certain material factors and assumptions were applied in providing these forward-looking statements. Forward-looking information involves numerous assumptions, including assumptions on the satisfaction of the conditions precedent to the closing of the Cresco transaction; the receipt of any necessary regulatory approvals in connection with the Cresco transaction; the impact of the Cresco transaction on the Company's current and future operations, financial condition and prospects; the value of the Cresco shares; the costs of the Cresco transaction and potential payment of a termination fee in connection with the Cresco transaction; the ability to successfully integrate with the operations of Cresco and realize the expected benefits of the Cresco transaction; the ability to sign and close divestiture transactions related to the Cresco transaction; access to public and private capital for buyers of assets being divested in relation to the Cresco transaction; the fact that marijuana remains illegal under federal law; the application of anti-money laundering laws and regulations to the Company; legal, regulatory or political change to the cannabis industry; access to the services of banks; access to public and private capital for the Company or Cresco; unfavorable publicity or consumer perception of the cannabis industry; expansion into the adult-use markets; the impact of laws, regulations and guidelines; the impact of Section 280E of the Internal Revenue Code; the impact of state laws pertaining to the cannabis industry; the Company's reliance on key inputs, suppliers and skilled labor; the difficulty of forecasting the Company's sales; constraints on marketing products; potential cyber-attacks and security breaches; net operating loss and other tax attribute limitations; the impact of changes in tax laws; the volatility of the market price of the Company's common shares; reliance on management; litigation; future results and financial projections; and the impact of global financial conditions and disease outbreaks; as well as those risk factors discussed under "Risk Factors" in Columbia Care's Form 10-K for the year ended December 31, 2022, filed with the applicable securities regulatory authorities and described from time to time in other documents filed by the Company with U.S. and Canadian securities regulatory authorities. The purpose of forward-looking statements is to provide the reader with a description of management's expectations, and such forward-looking statements may not be appropriate for any other purpose. In particular, but without limiting the foregoing, disclosure in this presentation as well as statements regarding the Company's objectives, plans and goals, including future operating results and economic performance may make reference to or involve forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. A number of factors could cause actual events, performance or results to differ materially from what is projected in the forward-looking statements. No undue reliance should be placed on forward-looking statements contained in this presentation. Such forward-looking statements are made as of the date of this presentation. Columbia Care undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The Company's forward-looking statements are expressly qualified in their entirety by this cautionary statement. This presentation contains future-oriented financial information and financial outlook information (collectively, "FOFI") about Columbia Care's revenue, gross margins and adjusted EBITDA, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. FOFI contained in this document was approved by management as of the date of this document and was provided for the purpose of providing further information about Columbia Care's future business operations. Columbia Care disclaims any intention or obligation to update or revise any FOFI contained in this document, whether because of new information, future events or otherwise, unless required pursuant to applicable law. Readers are cautioned that the FOFI contained in this document should not be used for purposes other than for which it is disclosed herein. Columbia Care#4STRATEGIC HIGHLIGHTS Key elements of the Columbia Care growth strategy and sustainable advantages 1 Diverse geographic footprint 2 Existing cultivation capacity 3 Innovative technology capabilities 4 Cannabist Retail Experience Presence in high- growth, emerging markets, with additional upside embedded in markets poised to transition to adult- use Capacity is built out and ready for expansion as markets evolve, with ample ability to grow into wholesale opportunities with minimal capital required Driving productivity initiatives and providing unique insights into consumers that informs strategic direction Unapologetic, inventive retail brand poised to expand across national footprint and provide best-in-class customer service 4 Columbia Care#5GROWTH CATALYSTS Multiple catalysts propelling growth in 2023 and beyond Optimization of canopy capacity in Vineland & adding 1 retail location in New Jersey to support growing market 3 additional retail locations to open in growing Virginia medical program; transition to adult use anticipated Maryland began adult-use sales on July 1 2023; 1 additional retail location in development Ramped cultivation & production capacity in ~1M sqft greenhouse in New York to be low-cost flower producer and wholesale supplier 5 active retail locations and the largest wholesale operation in West Virginia's growing market Increased product offerings in several markets, with plans to introduce additional high potency strains throughout the portfolio Expanded branded product distribution and Cannabist retail network; proprietary Forage platform to expand consumer insights Leveraging scaled cultivation capacity and continued growth of product distribution in wholesale channels LO 5 Columbia Care#6COMPANY OVERVIEW Optimizing Scale, Improving Efficiency and Growing Profitability Across Strategic National Platform 94 US Retail Locations (1) 31 US Cultivation & Manufacturing Facilities 血 16 Jurisdictions in US 4) 7232 1) 2) 3) $35B+ 2027 TAM in Licensed US States (2) +2M Sqft Cultivation & Production Capacity(3) $ 2 P $125M Q1 2023 Revenue 150+ Acres Outdoor Cultivation Capacity(3) 1% YoY Topline Revenue Growth in Q1 2023 VE 38% Q1 2023 Adj. Gross Margin (4) Pro forma facilities either open or under development. Does not include non-operational retail locations as of May 15, 2023 Estimated Sales figures from BDSA Market Forecast as of February 2023, broker research, company estimates Total capacity under existing licenses - additional development may be required to achieve Non-GAAP figure. See "Non-GAAP Financial Measures" on previous slides 6 Columbia Care™#7VERTICAL INTEGRATION ON NATIONAL SCALE UTAH COLORADO 526 4 CALIFORNIA 1 200 5 ARIZONA 2 2 PENNSYLVANIA 1 OHIO NEW YORK MASSACHUSETTS 3 2 8 го 1 1/ 3 5 NEW JERSEY 2 I www 3 DELAWARE 210 3 MARYLAND ILLINOIS WEST VIRGINIA 2 www 1 2 www 1 5 FLORIDA 4 14 WASHINGTON DC www 2 代 VIRGINIA 212 Vertically Integrated from Coast to Coast Operational In Development Wholesale Cultivation and Manufacturing Retail Locations * Open or under development; as of May 15, 2023; Pro forma facilities either open or under development. Does not include 4 non-operational retail locations as of May 15, 2023 www ם Wholesale Distribution in 15 Markets 31 Cultivation and Manufacturing Facilities 94 Retail Locations* (85 Active/9 In Development) Locations in development in 2023: VA - 3, NY - 4, NJ - 1, MD - 1 7 Columbia Care#8ONE OF THE MOST STRATEGICALLY POSITIONED MSOS Addressable market is >52% of the US population() with significant upside potential Columbia Care US Footprint Columbia Care Addressable Market (2) Adult Use Anticipated Medical Only Adult Use & Medical Pursuit Activity State Population (M) Est 2023 Sales (US$M) Est 2027 Sales (US$M) Status Licenses California 41.3 4,978.5 $ 6,576.5 Florida 22.2 $ 2,563.5 $ 4,503.3 Both Medical Unlimited Limited Illinois 12.7 $ 2,167.3 $ 2,632.7 Both Limited Massachusetts 7.0 1,799.3 $ 1,878.8 Both Limited Colorado 6.3 1,657.1 $ 1,833.8 Both Unlimited $35B+ Arizona 7.3 1,290.6 1,420.3 Both Limited New York 20.1 1,258.7 5,000.0(2) Both* Limited Projected 2027 TAM in Licensed US States(2) Pennsylvania 12.9 $ 1,204.9 $ 1,931.4 Medical Limited New Jersey 9.1 $ 1,121.6 $ 3,000.0(2) Both Limited Ohio 11.7 $ 518.3 $ 1,604.0 Medical Limited Maryland 6.2 479.9 $ 1,311.2 Both* Limited Conversion to Medical and Adult-Use Offers Significant Upside Columbia Care has experienced 3x-4x top-line revenue growth in states that have already converted from medical-only to medical and adult-use Adult-use sales launched in New Jersey (April 2022), in New York (January 2023, but MSO participation is pending), and in Maryland (July 2023) Columbia Care's strategic footprint is well positioned for the anticipated conversion of additional markets Utah Virginia West Virginia *Legislation passed, Columbia Care first sales in Adult Use pending 3.3 161.2 298.0 Medical Limited 8.7 $ 121.6 3,000.0(2) Both* Limited 1.8 52.2 83.7 Medical Limited Washington DC 0.7 $ 50.8 $ 133.8 Medical Limited Delaware 1.0 $ 39.8 $ 149.2 Medical Limited TOTAL 172.3 $ 19,465.3 $ 35,356.7 1) 2) US Census Bureau, Company estimates, Gallup poll, as of Nov 2020 Estimated Sales figures from BDSA Market Forecast as of February 2023, broker research, company estimates 8 Columbia Care#91) EMBEDDED UPSIDE IN TRANSITIONING GROWTH MARKETS Columbia Care in Virginia Columbia Care in New York Columbia Care in Maryland $1B+ Projected TAM(1) Leaf Medical Cannabis Leaf Medical Cannabis $3B+ Projected TAM(1) gLea gLeaf Medical Cannabis gLeaf $5B+ Projected TAM(1) 4 Retail Locations (3 Active, 1 In Development) ~59,040 sqft Existing Cultivation & Production Capacity ~3k sqft Additional Cultivation & Production Capacity 12 Retail Locations (9 Active, 3 In Development) ~147,765 sqft Existing Cultivation & Production Capacity ~30k sqft Additional Cultivation & Production Capacity 8 Retail Locations (4 Active, 4 In development) ~148k sqft Existing Cultivation & Production in Rochester and Phase 1 of Long Island greenhouse ~650k sqft Additional Cultivation & Production Capacity in Riverhead, NY; First Harvest Completed in Dec 2021 MARKET UPDATES Legislation signed, legalizing adult-use cannabis. Sales began on July 1, 2023, allowing for legal possession of up to 1.5 ounces of cannabis Existing operators will pay a fee to convert licenses from medical to adult-use Legislation proposes the issuance of 120 retail licenses, 25 grower licenses and 25 processing licenses, growing the wholesale opportunity in the state MARKET UPDATES • New regulations in effect July 1, 2022 removed the state registration card process. Patients are able to bring written certifications directly to dispensary, which has facilitated a growth in patient registrations to more than 45,000 Adult-use sales awaiting final legislation with an official start date. Legalizing possession and personal cultivation without providing for legal commerce is increasing pressure on lawmakers to work across the aisle to put forth a plan for a retail market Flower introduced to the medical market in September 2021 Estimated Sales figures from BDSA Market Forecast as of February 2023, broker research, Company estimates MARKET UPDATES On March 31, 2021 Legislation (S.854-A/A.1248-A) was signed, legalizing adult-use cannabis and expanding medical marijuana; adult use expected in 2023 and regulator communicated the intent for medical companies to wholesale to initial social equity retailers Access to the medical cannabis program has expanded; whole cannabis flower entered market in October 2021 Columbia Care is among existing Registered Organizations that will be able to operate up to 8 retail locations (5 medical + 3 co-located medical/adult-use) and remain vertically integrated 9#10California LOW-COST CULTIVATION, EFFICIENT & SCALABLE PRODUCTION 28 operational / in development facilities with +2 million sq. ft of cultivation and manufacturing capacity Jurisdiction Arizona Facility Count 2 Total Size (sqft) 34,800 45,572 Status Operational Operational Colorado 3 108,227 Operational 20,000 Operational Delaware 2 37,524 Under development Florida 4 105,373 Operational Illinois 1 32,802 Operational Maryland 2 59,040 Operational Massachusetts 1 38,890 Operational New Jersey 2 320,724 Operational New York 2 798,346 Operational Ohio 2 117,722 Operational Pennsylvania 1 274,000 Operational Virginia 2 147,765 Operational Washington DC 2 16,591 Operational West Virginia 1 39,293 Operational Total(1) 28 2,196,219 Does not include 3 non-operational, Columbia Care licensed facilities 10 Columbia Care#11FINANCIAL HIGHLIGHTS (in US$ thousands) FY 2022A Q2 2022A Q3 2022A Q4 2022A Q1 2023A P&L Cash Flow Revenue 511,578 129,571 132,733 126,187 124,535 Adj. EBITDA 67,377 12,029 20,993 17,523 16,364 Interest Expense 48,349 11,484 12,974 12,647 12,573 Capital Expenditure 73,887 29,162 11,851 3,363 5,724 Balance Sheet Cash 48,154 81,440 50,023 48,154 40,159 PP&E 357,993 373,877 370,820 357,993 348,581 Total Assets 1,086,066 1,420,465 1,371,578 1,086,066 973,021 Total Liabilities 850,716 892,496 870,701 850,716 791,696 Shareholder's Equity 235,350 527,969 500,877 235,350 181,325 Note: Results are reported in US GAAP 11 Columbia Care#1277 Tempe, AZ WOWE CING PREM FLOVER FLOW STRA 1712706 aree SEED & STRAIN CANNABIS CO 1/8 oz FLOWER Resk INDICA SEED&STRAIN FLOWER 1/8 oz FLOWI SEED& STRA CANN A HIGHER KNOWLEDGE A CALL BRANDS TRIPLE SEV Med ה ה ה ה TRIPLE SEVEN aparalleled CANNABIST TRIPLE SEVEN unparalleled PREROLL wwwwwwwwe#13CANNABIST EXPERIENCE Columbia Care's new retail storefront experience is centered on making shopping simple and approachable for the vast range of experience levels as cannabis use is normalized and legalized across the US, with knowledgeable staff and technology-enhanced interaction. 35 Cannabist Locations Opened to Date • Tempe, AZ Deptford, NJ • Morgantown, WV • San Diego, CA • All 14 FL locations • Chicago, IL • Villa Park, IL • Virginia Beach, VA . Vineland, NJ • Lowell, MA • Williamstown, WV • Portsmouth, VA • Springville, UT • Beckley, WV • Carytown, VA • Boston, MA • Brooklyn, NY • Williamstown, VA . St. Albans, WV . Near-term Pipeline Huntington, WV • Norfolk, VA 1 Virginia location; 1 New Jersey location Early Insights - Cannabist Rebrand Impact Villa Park, IL Case Study (1) +15% increase in revenue +19% increase in number of transactions Top 3 all-time highest weekly sales occurred since rebrand 1) Comparison of first 7 full weeks of operation as Cannabist to prior 7 weeks of operation prior to rebrand A Higher Experience A Higher Experience 13#14BUILDING NATIONAL BRAND AND PRODUCT PORTFOLIO Growing our proprietary brand footprint through expanded market penetration and wholesale reach In-house brands accounted for over 60% of all flower sold at Columbia Care owned 徵 dispensaries in Q1 2023. Owned brands also made up over 47% of sales in Q1 2023 Wholesale SKU distribution available in 15 markets in 2022 SEED & STRAIN CANNABIS CO SEED& STRAIN CANNABIS CO 1/802 FLOWER измот 200/1 FLOWER SEED & STRAIN CANNABIS CO FLOWER PRES DES PRESS SHINE CLASSIXO SPAFINIS M Columbia Care house brands are currently available in all 16 operational markets Hedy $ Columbia Care currently has 55 3 different product categories across its house brands GUMMIES C LASSY 00 BOOMBOX BOOWBOX TRIPLE SEVEN 3.5 GRAMS 1/8 OUNCE SATIVA AMBER LIVE RESIN CARTRIDGE NET VOL 1 mL (0.0338 fl. oz) AMBER unparalleled AMBER unparalleled PREROLL 1 GRAM 14#15SEED & STRAIN ESTD CANNABIS CO 2020 ROOTED IN LAND & HARVESTED BY HAND We believe in the naturally restorative properties of cannabis and we proudly propagate that belief by sharing our bounty of flower with you. Upscale yet accessible, Seed & Strain is the most widely distributed brand across the entire portfolio. Available in 14 markets, Seed & Strain is a 2021 High Times Award Winner, winning 2nd Place in the Best Indica Flower category (Velvet Glove) and 2nd place in the Best Pre-Roll category (Cherry Chem). HIGH TIMES CUP CANNABIS ILLINOIS 202 WINNER Uplift |SATIVA ELEVATE YOURSELF SEED & STRAIN PRE-ROLL FROM ROOT TO RISE SEED & STRAIN CANNABIS CO 19 VAPE CARTRIDGE Balance HYBRID SEED & STRAIN FLOWER 1/8 oz FLOWER#16Ī Same Quality, Better Vibe. Our Cannabis is at the uppermost end of the quality spectrum, and our strains are unwavering in consistency. We've gone above and beyond the highest industry standards to cultivate the best strains that deliver every time. Our ultra-premium brand has national penetration and is now available in 11 markets. Triple Seven has won multiple awards in the Illinois High Times Cannabis Cup, including 1st Place Hybrid Flower and 3rd Place Sativa Flower, and the California High Times Cannabis Cup, including 2nd place Sativa Flower and 3rd Place Indica Flower. HIGH TIMES CUP CANNABIS ILLINOIS 2021 WINNER HIGH TIMES CANNABIS 20 22 CUP 2nd PLACE WINNER SOCAL HIGH TIMES CANNABIS CUP 20322 3rd PLACE WINNER SOCAL 7 TRIPLE SEVEN 3.5 GRAMS 1/8 OUNCE unparalleled TRIPLE SEVEN unparalleled PREROLL 1 GRAM#17CLASSIX AMPLIFY TODAY Classix is our every day, timeless lifestyle brand that celebrates incredible cannabis moments shared with friends. Now available in 14 markets, Classix successfully launched in 5 markets (AZ, MA, IL, DE, & NJ), and represented the single largest launch week for a brand in Columbia Care history totaling 12% of all sales on day 1, and 14% of all sales after the first week*. The launch of Classix also marked industry's widest multi- state flower brand launch in a single day. CLASSIX FREMIUMS AM FM SPRE ROLLS 2022 MARCOM CLASSIX PLATINUM WINNER *Note: For markets in which the product is available PREMIUM CANNABIS FLOWER A BOOMBOX BOOWBOX C - S OUT CLASSIX A PREMIUM CANNABIS FLOWER СУИНУВ ЕГОМЕН LKEWIOW 26 3.5G 18OZ 3'2005#18Hedy Goodness in every dose Our fast acting, delicious cannabis-infused edibles. Whichever path you choose, it's always an exhilarating one. With HEDY the sky's the limit. Infused with Azuca fast-acting TIME INFUSION TM, allowing high-quality cannabinoids to take effect in a groundbreaking, consistent, and predictable two to fifteen minutes. In Q4 2022, Hedy launched across six markets (AZ, CO, DE, MA, MO, VA), and has since expanded into three additional markets (IL, NY & NJ). Hedy is currently available in the following form-factors: gummies, chocolate drops, chocolate bar and effects-based gummies. Hedy Cannabis-infused gummies 2022 MARCOM GOLD WINNER We anticipate the launch of additional markets and form factors in 2023. GUMMIES#19TYSON VIA E (0.0350Z.) D AMIES NCH MUNC MIES GUMMI NCH MUNCH MUNC UMMIES GUMMIES G UNCH MMIES MUCH SUAN ES HUNCH ACHUN UM CH MI MIES GUM CH MU IM TYSON MU UMMIES MUNCH MO UMMIES GUMM INCH MUNC RIFS GUN MMU UM MU GUMMES MUNCH TYSON Columbia Care 97 East Masten Crole Milford, DE 19963 NET WT FLOWER PRE-ROLL GUMMIE UNCH M GUMMIL MUSCH ESC AUNCH MUNCH ICH my S G A MMES ON UN AMI MMIES G CH MU H MU MIKE BITES SUMM TYSON UNDISPUTED CANNABIS NET WT. 3.5G | 0.1230Z TYSON TYSON IS BACK. Tyson 2.0 is an extraordinary balance of premium and affordable, full-spectrum cannabis flower, concentrates, and consumables available at retailers nationwide. Tyson 2.0 launched with Columbia Care as its exclusive national cultivation and manufacturing partner. Tyson 2.0 currently offers 3.5g flower, a 0.5g pre-roll and 28g flower and is sold through both our wholesale and retail channels. Tyson 2.0 launched in December 2021 and is currently available in 10 Columbia Care markets: AZ, CA, CO, DE, DC, MD, PA, IL, MA and OH.#20AMBER Formulations crafted by connoisseurs Vibes crafted by you Our customers have nominated AMBER for San Diego's Best Concentrate Product and Best Overall Concentrate Brand 2022. LIVE RESIN CARTRIDGE Additional products launched in multiple markets during Q4 2022, including AMBER Diamonds, Cured Crumble, Diamond Sauce, Live Resin and Shatter. AMBER is now available in 10 markets (AZ, CA, CO, DC, DE, IL, MA, NJ, PA, WV). NET VOL 1 ml (0.0338 fl.oz) SATIVA AMBER AMBER SHATTER ONE CARTRIDGE 0.5ml NET VO AMBER SHATTER CARTRIDGE#21SHINE PRESS YOU, UPGRADED Ready to fine tune your day? High potency and high quality aren't mutually exclusive. Take control of your cannabis with hard pressed THC tablets formulated by industry experts for morning, day and night. The choice is yours. The pleasure is ours. PRESS 2.0 was created as a portable, convenient, and discreet option. Shine, Rally and Doze feature fast-acting cannabis and special formulations designed for morning, afternoon, and night routines. The new PRESS 2.0 hard-pressed tablets are now available in nine markets (CA, DE, FL, MA, NJ, VA, UT, IL, WV), with launches in additional states planned, pending regulatory approvals.#22ENERGETIC K EUPHORIC A RETAIL PLATFORM BUILT FOR CONTINUOUS INNOVATION How do you want to feel today? ← RELAXED Technology and efficiency innovation will continue to heighten the in-store and at-home shopping experience at Cannabist and create an all-encompassing ecosystem from home to dispensary and online. Forage is our award-winning online cannabis discovery tool that matches strain and product recommendations to how you want to feel. We are the first cannabis company to bring a technology solution like this to the market that offers a truly unique consumer experience. Since the launch of Forage in June 2021, we have seen increased adoption on mobile and in the way the product is being leveraged in stores. We are continuing to explore opportunities around branded advertising and engaging content. RELAXED 22 22 RO How do you want to use it? How do you want to feel today? Find The Right Cannabis Pa Edbly TINGLY#23SC STASH CASH Stash Cash app offers a streamlined shopping experience to build and track loyalty rewards, shop from anywhere and discover new products. DOWNLOAD TODAY App Store 6000 SC STASH CASH 2:12 B Home SC STASH CASH Mary Jane [email protected] Your points balance: 420 Cannabist San Diego Directions Your deals Call 23 The Stash Cash app is a platform for customers to build loyalty rewards, shop from anywhere and discover new products Stash Cash has features that allow users to set their favorite dispensary and shop, earn and redeem points for purchases made, discover new products using Forage, connect via social media. and much more Earn rewards for enjoying cannabis. It doesn't get any simpler than that. Build your stash, save your cash CANNABIS REWARDED#2424 24 AWARD-WINNING PRODUCTS & SERVICES • • • High Times Cannabis Cup Illinois 2021 • Hybrid Flower 1st Place: Triple 7, Rainbow Runtz Indica Flower 2nd Place: Seed & Strain, Velvet Glove Pre-Roll 2nd Place: Seed & Strain, Cherry Chem Sativa Flower 3rd Place: Triple 7, Tropical Runtz High Times Cannabis Cup California 2022 Sativa Flower 2nd Place: Triple 7, Super Boof Indica Flower 3rd Place: Triple 7, Pancakes #7 High Times Cannabis Cup Illinois 2022 Pre-Roll 3rd Place: Triple 7, Tropical Runtz Clio Cannabis Awards 2021 • Clio Cannabis Bronze Award: Forage, Digital/Mobile E-Commerce Category WEEDCon 2021 Harvest Cup • • Best Flower - Hybrid: Triple 7, Peanut Butter Breath MarCom 2021 Gold Award: Forage, Mobile Buying Experience Category Platinum Award: Cannabist, Branding Refresh Category MarCom 2022 Gold Award: Hedy, Marketing/Promotion Category • Platinum Award: Classix, Design (Print) Category SEED & STRAIN CANNABIS CO TR7PLE SE7EN Hedy 777 TR7PLE SE7EN Errl Cup 2023 • Isolate Category 1st Place: Amber, Dat Flava Diamond Dust AMBER™ AMBER™* Farmers Cup 2023 • People's Choice Award for Best Appearance: Amber, Lemon Meringue Live Resin Vape, Licensed Vape Carts Category Solvent Dabs Category 3rd Place: Amber Snow White Diamonds and Sauce#25Columbia Care™